-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On June 18, Eisai and Bristol-Myers Squibb (BMS) announced that the two companies have reached an exclusive global strategic cooperation agreement on the joint development and cooperation of the commercialization of an ADC drug MORAb-202
.
Antibody-drug conjugate (ADC) connects a biologically active small molecule drug to a monoclonal antibody through a chemical link, and the monoclonal antibody acts as a carrier to target the small molecule drug to target cells
.
MORAb-202 is Eisai’s first ADC drug.
MORAb-202 is Eisai’s first ADC drug.
According to the financial terms of the agreement, Bristol-Myers Squibb will pay Eisai US$650 million, of which US$200 million will be used to pay Eisai’s research and development expenses
.
Eisai also has the right to receive up to $2.
Bristol-Myers Squibb will pay Eisai US$650 million, of which US$200 million will be used to pay Eisai’s research and development expenses
"MORAb-202 combines the antibodies and payloads found inside Eisai, using the company's advanced chemical capabilities,
" said Eisai CEO Haruo Naito
.
"It is characterized by its payload eribulin (eribulin ), eribulin final commercial synthetic route for up to 62 steps, called the peak of medicinal chemistry community
Eribulin ORR-PFS-OS data
Just in May of this year, Eisai recently announced in Advances in Therapy the evaluation of the original anticancer drug Eribulin (Eribulin)-Halaven (Chinese trade name: Hailewei, common name: elibu mesylate) Lin, eribulin mesylate) data from a real-world study on the treatment of metastatic breast cancer (mBC)
.
The study evaluated the treatment model and clinical results of Halaven as a third-line or multiple-line therapy for mBC patients, including triple-negative breast cancer (TNBC) subtypes
Havalen is a synthetic halichondrin (halichondrin B) analogue, which is a tubulin polymerization inhibitor with a novel mechanism of action
.
Halichondrin B is a substance found on black sponges that grow along the coast of Japan, and can effectively cure tumors
"This global cooperation with Eisai is an important strategic fit for Bristol-Myers Squibb, as it expands our leading position in oncology through differentiated assets and complements our extensive solid tumor product portfolio.
And take advantage of our deep in-house development expertise
.
" said Giovanni Caforio, MD, Chairman and CEO of Bristol-Myers Squibb
However, ADC drugs have been facing considerable challenges in recent years, both in clinical and commercialization
.
As of now, only a few products have been successfully launched on the market
Reference materials:
https:// 202-Antibody-Drug-Conjugate
https:// 202-Antibody-Drug-ConjugateLeave a message here
